Alzheimer's Disease clinical trials at UCSF
20 in progress, 7 open to eligible people
Alzheimer's disease is a brain disorder that affects memory and thinking. UCSF is studying a new PET tracer to check brain changes in dementia. Other trials look at how music affects social connections in Alzheimer's and how early-onset cases progress over time. UCSF uses imaging to spot signs of Alzheimer's disease for improved understanding.
First-in-Human Evaluation of an Astrocytic Glutamate Transporter (EAAT2) PET Tracer in Dementia
open to eligible people ages 40-75
This is a first in human study that will assess the safety and diagnostic performance of [18F]RP-115 (fluorine-18 labeled RP115), a positron emission tomography (PET) agent. This agent has the potential to identify the early changes that occur in…
San Francisco, California
Music, Social Attention, and Dementia
open to eligible people ages 55-89
This is an exploratory mixed-methods control-treatment study to evaluate if participation in rhythmic musical activities improves social attention and connectedness in individuals living with mild to moderate bvFTD and AD, and their caregivers.…
San Francisco, California
PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers
open to eligible people ages 18-80
This is a Phase 1/2 study to evaluate the safety and tolerability of 18F-OP-801 in subjects with ALS, AD, MS, PD and age-matched HVs. 18F-OP-801 is intended as a biomarker for PET imaging of activated microglia and macrophages in regions of…
San Francisco, California and other locations
Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease
open to eligible people ages 50-80
The purpose of this study is to assess the effectiveness, safety, and tolerability of BMS-986446 an Anti-MTBR Tau Monoclonal Antibody in participants with Early Alzheimer's Disease.
San Francisco, California and other locations
Alzheimer's Disease Neuroimaging Initiative 4
open to eligible people ages 55-90
Since its launch in 2004, the overarching aim of the Alzheimer's Disease Neuroimaging Initiative (ADNI) Study has been to validate biomarkers for Alzheimer's disease (AD) clinical trials. ADNI4 continues the previously funded ADNI1, ADNI-GO, ADNI2,…
San Francisco, California and other locations
Characterizing Cognitive Decline in Late Life Depression: The ADNI Depression Project
open to eligible people ages 65 years and up
The purpose of this research study is to characterize the mechanisms contributing to cognitive impairment and accelerated cognitive decline in Late Life Depression (LLD). This is a non-randomized, observational, non-treatment study that originally…
San Francisco, California and other locations
Longitudinal Early-onset Alzheimer's Disease Study Protocol
open to eligible people ages 40-64
The Longitudinal Early-onset Alzheimer's Disease Study (LEADS) is a non-randomized, natural history, non-treatment study designed to look at disease progression in individuals with early onset cognitive impairment. Clinical, cognitive, imaging,…
San Francisco, California and other locations
Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
Sorry, in progress, not accepting new patients
The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer's disease. Additional participants will be enrolled to an addendum safety cohort. The participants will be administered…
San Francisco, California and other locations
E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease
Sorry, not currently recruiting here
The primary objective of the study is to determine the dose response of E2814, when concurrently administered with lecanemab, on the change from baseline at 18 months in cerebrospinal fluid (CSF) microtubule-binding region (MTBR)-tau-243 in…
San Francisco, California and other locations
Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease
Sorry, in progress, not accepting new patients
This study will be conducted to evaluate the efficacy of lecanemab in participants with early Alzheimer's disease (EAD) by determining the superiority of lecanemab compared with placebo on the change from baseline in the Clinical Dementia Rating-Sum …
San Francisco, California and other locations
Learn About the Safety of BIIB080 Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age
Sorry, in progress, not accepting new patients
In this study, researchers will learn more about a study drug called BIIB080. The study will focus on participants with mild cognitive impairment or mild dementia due to AD. The main question researchers are trying to answer is if BIIB080 can slow…
San Francisco, California and other locations
AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid
Sorry, in progress, not accepting new patients
The primary purpose of this study is to determine whether treatment with lecanemab is superior to placebo on change from baseline of the Preclinical Alzheimer Cognitive Composite 5 (PACC5) at 216 weeks of treatment (A45 Trial) and to determine…
San Francisco, California and other locations
Alzheimer's Tau Platform: Master Protocol
Sorry, not yet accepting patients
The goal of the Alzheimer's Tau Platform (ATP) is to evaluate the safety and effectiveness of tau-directed therapies, alone or in combination with donanemab, in adults aged 50-80 with late preclinical or early prodromal Alzheimer's disease. This…
Head-to-Head Harmonization of Tau Tracers in Alzheimer's Disease
Sorry, in progress, not accepting new patients
The purpose of this study is to compare/harmonize cross-sectional and longitudinal tau tangle measurements obtained with the tau PET radiopharmaceuticals Flortaucipir and MK-6240 to elucidate the advantages and caveats of their use in clinical…
San Francisco, California and other locations
Brain Health Study: A Pragmatic, Patient-Centered Trial
Sorry, in progress, not accepting new patients
The eRADAR Brain Health Study seeks to refine and test a novel, low-cost strategy for increasing dementia detection within primary care.
San Francisco, California and other locations
Care Ecosystem Consortium Effectiveness Study
Sorry, in progress, not accepting new patients
The Care Ecosystem is an accessible, remotely delivered team-based dementia care model, designed to add value for patients, providers and payers in complex organizational and reimbursement structures. Care is delivered via the phone and web by…
San Francisco, California and other locations
Alzheimer's Plasma Extension
Sorry, in progress, not accepting new patients
The APEX study is a multicenter, observational study designed to capture longitudinal follow-up of plasma biomarkers and cognitive and functional assessments on individuals who screen failed in the AHEAD study over approximately 4 years.…
San Francisco, California and other locations
Living Alone in Old Age With Cognitive Impairment
Sorry, in progress, not accepting new patients
The purpose of this study is to better understand the experience of living alone in older age with cognitive impairment. We recruit adults 55+ living alone with cognitive impairment such as Alzheimer's disease or mild cognitive impairment. This…
San Francisco, California
Quality Improvement and Clinical Utility PrecivityAD2(TM) Clinician Survey
Sorry, in progress, not accepting new patients
There is a major unmet need for timely, non-invasive, and low-burden evaluation of patients presenting with mild cognitive impairment (MCI) and dementia. MCI impacts 12-18% of people in the United States over age 60 years (Alzheimer's Association.…
San Francisco, California and other locations
DIAGNOSE CTE Research Project-II
Sorry, accepting new patients by invitation only
Each year, millions of people are exposed to repetitive head impacts (RHI) through contact sports. RHI can result in concussions and asymptomatic non-concussions to confer risk for Alzheimer's disease (AD) and related dementias (ADRD) including…
San Francisco, California and other locations
Our lead scientists for Alzheimer's Disease research studies include David Wilson, MD, PhD Scott Mackin, Ph.D. Gil Rabinovici, MD Aaron Colverson, PhD Vinil Shah Duygu Tosun, Ph.D. Deborah Barnes, PhD Charles Windon Elena Portacolone, PhD MPH MBA Katherine L Possin, PhD.
Last updated: